Australia covid-19 infection donates patient Australia

CSL Behring Australia joins race for Covid-19 therapy development

Reading now: 950
www.pharmaceutical-technology.com

The Australian subsidiary of CSL Behring is set to develop a plasma-derived therapeutic for the treatment of serious complications in Covid-19 patients.

The company intends to focus on patients whose infection is progressing to the requirement for ventilation. Named Covid-19 Immunoglobulin, the therapeutic will be developed by CSL Behring Australia at its manufacturing facility in Broadmeadows, Victoria.

The first part of the development project will involve production and use of a small batch of Covid-19 Immunoglobulin to create tests for detecting the presence of the antibodies against SARS-CoV-2, the novel coronavirus that causes Covid-19.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA